Choroidal Melanoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Choroidal melanoma is the second most common type of primary malignant melanoma in the body and one of the most common primary malignant intraocular tumors. Even so, the tumor is only occasionally found. Choroidal melanomas are a uveal melanoma subtype. Every million people, there are approximately 6 cases of primary choroidal melanoma. The southern latitudes of the United States appear to have a higher incidence of uveal melanoma, possibly as a result of more solar exposure. The sporadic cancer known as choroidal melanoma affects adults' eyes. There may be no signs at all for a number of years prior to symptoms developing. The symptoms are influenced by the tumor's exact location within the eye, size, and whether it is directly or indirectly harming the retina.

Description

Choroidal melanoma is the second most common type of primary malignant melanoma in the body after intraocular primary malignant tumors. The tumor is only occasionally found in spite of this. Choroidal melanomas are a subclass of uveal melanomas. The two types of uveal melanomas are: (1) anterior uveal melanomas, where the tumor develops in the iris, and (2) posterior uveal melanomas, where the tumor develops in either the choroid or the ciliary body. Intraocular melanomas have the potential to impact numerous uveal structures simultaneously. Malignant tumors originate in the ocular tissue known as the uvea, an extremely pigmented layer that is a part of the eye's wall. The uvea is made up of three parts: the iris, ciliary body, and choroid. The choroid supports the pigment epithelium of the retina and runs the length of the ocular fundus. The uvea's main function is to provide energy for the retinal photoreceptors, which have a high metabolic demand.

Choroidal Melanoma (Epidemiology)

Primary choroidal melanoma affects about 6 people out of every million. Uveal melanoma appears to be more common in the southern latitudes of the United States, possibly as a result of increased solar exposure. This could also be a result of retired Americans choosing to live in the South. The risk of developing choroidal melanoma peaks around age 55. Despite being a relatively uncommon tumor among Asians, research indicates a peak incidence at a younger age. Choroidal melanoma in kids is uncommon. Choroidal melanoma is seen slightly more frequently in men overall, with the exception of the 20-39 age range, where there is a slight preference for women. The choroidal melanoma and other uveal melanomas affect white people of northern European ancestry more frequently. It is very uncommon for black people to have choroidal melanoma. Hispanics and Asians are believed to have a modest but intermediate risk when compared to whites and Black people.

Choroidal Melanoma -Current Market Size & Forecast Trends

The market for choroidal melanoma, a rare form of eye cancer, is part of the broader eye melanoma treatment market, which is expected to grow from approximately USD 9.1 billion in 2024 to about USD 12.61 billion by 2028, reflecting a compound annual growth rate (CAGR) of 8.5% during this period. The growth is attributed to increasing awareness and early detection, advancements in treatment modalities such as targeted therapies and immunotherapies, and an aging population that is more susceptible to various forms of cancer, including melanoma. North America is anticipated to maintain the largest market share due to its advanced healthcare infrastructure and significant investments in cancer research. Meanwhile, the Asia-Pacific region is expected to exhibit the fastest growth rate, driven by rising healthcare access and ongoing public health initiatives aimed at improving cancer outcomes. As research continues to evolve and new therapies are developed, the market for choroidal melanoma is likely to expand further through 2035.

The sporadic cancerous condition known as choroidal melanoma affects adults' eyes. There may be no symptoms at all for a number of years prior to the onset of symptoms. The specific location and size of the tumor within the eye, as well as whether or not the tumor is also indirectly affecting the retina, all have an impact on the symptoms. Some of the symptoms include double vision (diplopia), blurred vision, eye pain, flashes of light, a reduction in one's overall field of vision, and blindness. Other CM symptoms include the perception of a foreign body in the field of vision (floaters), redness, swelling or displacement of the eye, a change in the shape of the pupil, and pressure inside the eye. Metamorphopsia is the name given to this. There is a possibility that it will spread to various bodily areas. Ocular melanoma metastasis typically affects the liver, though it can also harm the lungs, skin or soft tissue, bone, or other organs in 20% of cases. According to some estimates, 40 to 50% of people who have ocular melanoma will develop metastases. Clinical trials for drugs like Belzupacap sarotalocan (Aura Biosciences), Carmustine (Thomas Jefferson University), and others have been started by the majority of businesses and universities to address the numerous unmet needs.

Report Highlights

Choroidal Melanoma - Current Market Trends

Choroidal Melanoma - Current & Forecasted Cases across the G8 Countries

Choroidal Melanoma - Market Opportunities and Sales Potential for Agents

Choroidal Melanoma - Patient-based Market Forecast to 2035

Choroidal Melanoma - Untapped Business Opportunities

Choroidal Melanoma - Product Positioning Vis-a-vis Competitors' Products

Choroidal Melanoma - KOLs Insight